Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia
JC Fitzgerald, SL Weiss, SL Maude… - Critical care …, 2017 - journals.lww.com
Objective: Initial success with chimeric antigen receptor–modified T cell therapy for
relapsed/refractory acute lymphoblastic leukemia is leading to expanded use through
multicenter trials. Cytokine release syndrome, the most severe toxicity, presents a novel
critical illness syndrome with limited data regarding diagnosis, prognosis, and therapy. We
sought to characterize the timing, severity, and intensive care management of cytokine
release syndrome after chimeric antigen receptor–modified T cell therapy. Design …
relapsed/refractory acute lymphoblastic leukemia is leading to expanded use through
multicenter trials. Cytokine release syndrome, the most severe toxicity, presents a novel
critical illness syndrome with limited data regarding diagnosis, prognosis, and therapy. We
sought to characterize the timing, severity, and intensive care management of cytokine
release syndrome after chimeric antigen receptor–modified T cell therapy. Design …